Search results
Results from the WOW.Com Content Network
April 11, 2024 at 10:09 AM. (Reuters) -Moderna said on Thursday it had paused its plans to build a vaccine manufacturing facility in Kenya, following a post-pandemic decline in demand for COVID-19 ...
The COVID-19 pandemic in Kenya was a part of the worldwide pandemic of coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The virus was confirmed to have reached Kenya on 12 March 2020, [3] with the initial cases reported in the capital city Nairobi and in the coastal area Mombasa .
Kenya had an estimated 5 million malaria cases and over 12,000 deaths reported in 2022, according to the World Health Organization. Most of those affected are children under 5 and pregnant women.
Share of people who received at least one dose of COVID-19 vaccine in the world. COVID-19 vaccination programs are ongoing in the majority countries and territories in Africa, with 51 of 54 African countries having launched vaccination programs by July 2021. [1] As of October 2023, 51.8% of the continent's population is fully vaccinated with ...
The Moderna COVID‑19 vaccine, sold under the brand name Spikevax, is a COVID-19 vaccine developed by the American company Moderna, the United States National Institute of Allergy and Infectious Diseases (NIAID), and the Biomedical Advanced Research and Development Authority (BARDA). Depending on the jurisdiction, it is authorized for use in ...
A study on the effectiveness of a first dose of the Pfizer–BioNTech or Oxford–AstraZeneca COVID-19 vaccines against COVID-19 related hospitalisation in Scotland was based on a national prospective cohort study of 5.4 million people. Between 8 December 2020 and 15 February 2021, 1,137,775 participants were vaccinated in the study, 490,000 of ...
SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), the virus that causes COVID-19, was isolated in late 2019. [1] Its genetic sequence was published on 11 January 2020, triggering an urgent international response to prepare for an outbreak and hasten the development of a preventive COVID-19 vaccine.
COVID-19 Vaccines Global Access (COVAX) is one of its four pillars. It is a worldwide initiative aimed at equitable access to COVID-19 vaccines directed by the GAVI vaccine alliance, the Coalition for Epidemic Preparedness Innovations (CEPI), and the WHO, alongside key delivery partner UNICEF.